Vanda Pharmaceuticals (NASDAQ: VNDA) shares surged 44% after-hours following FDA approval of its new drug BYSANTI for treating Bipolar I manic episodes and Schizophrenia symptoms in adults. The approval marks Vanda's second FDA win in less than two months, following December's approval of NEREUS™. BYSANTI, also known as milsaperidone, received expedited approval due to its bioequivalence to the older drug Fanapt.

This is a major breakthrough for Vanda, as BYSANTI has been categorized as a New Chemical Entity with patent protection extending through 2044. The designation typically comes with robust patient protection, meaning Vanda won't face generic competition for nearly two decades. The drug demonstrates bioequivalence to iloperidone (marketed as Fanapt®) while offering a trusted safety profile backed by over 100,000 patient-years of real-world data.

The drug's future appears promising, with current trials testing BYSANTI as a treatment for major depressive disorder. Results expected by the end of 2026 could significantly expand its market size and future revenues. With a market cap currently reflecting a Sell or Flat analyst consensus, this back-to-back approval streak could force a re-evaluation of VNDA's growth trajectory.